Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Multiple myeloma (MM ... This review will focus on MM antigens and their specific antibodies. These monoclonal antibodies are an attractive therapeutic tool for MM humoral immunotherapy, with ...

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

We're excited in the multiple myeloma that we continue to ... and also bispecific antibodies. So some of the pipeline that we're looking for is agents that are used without a step up priming ...

I mean, with all the development we've seen in multiple myeloma ... in rural areas who may not have access even to bispecific antibodies, which you can argue can be given without the need of ...

The publication of the pricing and reimbursement decision for Pepaxti (melflufen) in the Gazetta Ufficiale removes the last ...

Paris: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products ...

Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, ...

20% of patients had a best clinical response of SD Elotuzumab (HuLuc63), a humanized mAb CS1 High expression on the surface of MM cell lines and on plasma cells from MM patients 24 ADCC against MM ...